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Left Bundle Branch Block
After Transcatheter Aortic Valve
Implantation
Still a Matter of Concern?*
Laurent Roten, MD, Bernhard Meier, MD
Bern, Switzerland
Transcatheter aortic valve implantation (TAVI) has experi-
enced unprecedented growth since its ﬁrst description by
Alain Cribier in 2002 (1) and is now routinely performed in
many institutions worldwide. New-onset left bundle branch
block (LBBB) or atrioventricular (AV) block necessitating
permanent pacemaker implantation (PPI) are among the
most frequent complications of TAVI (2–5). Case reports
describing late occurrence of complete AV block and the
fact that LBBB has been associated with a worse outcome
after surgical aortic valve implantation led clinicians to adopt
a generous strategy of pacemaker implantation after TAVI.
This strategy was further enhanced by the urge to ambulate
patients early after TAVI instead of prolonged monitoring
for resolution of AV conduction impairment. ImprovementSee page 128of valve design and implant strategy has lowered the rate of
AV conduction abnormalities, but they continue to be a
matter of concern. Moreover, new-onset LBBB after TAVI
was associated with increased mortality in a study by Hou-
thuizen et al. (3), whereas others have found no association
(4,6–8). Additional insights into the outcome of patients
with LBBB after TAVI are therefore needed.
In this issue of JACC: Cardiovascular Interventions, Urena
et al. (9) evaluate the impact of new-onset LBBB on the
outcome in 668 patients undergoing TAVI with a balloon-
expandable valve. New-onset persistent LBBB was found in
11.8% of patients. Compared with the remaining patients,
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paper to disclose.failure hospitalizations during follow-up. However, new-
onset LBBB was associated with a higher rate of PPI, a lack
of left ventricular ejection fraction (LVEF) improvement,
and poorer functional class at follow-up.
There are 2 hypotheses about how new-onset LBBB can
increase mortality after TAVI: it is a harbinger of 1) sudden
cardiac death; and 2) dyssynchrony-induced progressive
heart failure culminates in increased cardiovascular mor-
tality. Table 1 gives an overview of the most important
studies reporting on new-onset LBBB after TAVI and
mortality. Houthuizen et al. (3) found an association with
increased mortality. So far, other groups were not able to
conﬁrm this result, including the study under discussion
here. What are the reasons for this discrepancy? Houthui-
zen et al. (3) included lower-risk patients, but their inci-
dence of new-onset LBBB and PPI after TAVI was
signiﬁcantly higher, even though a balloon-expandable valve
was implanted in a signiﬁcant proportion of patients. This
could be the result of differences in implantation technique,
which may also have affected outcome. Furthermore, pa-
tients with any new-onset LBBB were analyzed by Hou-
thuizen et al. (3), whereas in the other studies, the focus was
on patients with new-onset persistent LBBB. This detail
might have important consequences. It is well described
that as many as 50% of new-onset LBBB cases resolve
within a short time after TAVI (4,7). However, those pa-
tients could still be at risk of late occurrence of complete
AV block, and excluding those patients might affect
outcome. Because of a higher incidence of new-onset
LBBB in the study by Houthuizen et al. (3) and longer
follow-up, the study probably also had more power to detect
any differences. In the study by Urena et al. (9), 4% of
deaths were sudden, compared with 17% in the study by
Houthuizen et al. (3). Thus, patients often died of different
causes before sudden cardiac death occurred, further
obscuring the effect of new-onset LBBB on mortality and
limiting the power of the study.
None of these studies reported in detail the PPI strategy
and timing. However, the timing of PPI after TAVI is
important. It is possible that complete AV block resolves
after TAVI and complete LBBB may remain. If a perma-
nent pacemaker is implanted early, those patients would not
show up in the group of patients with new-onset LBBB at
hospital discharge, as they are excluded. However, if PPI is
performed only after several days, complete AV block might
have resolved to complete LBBB in some patients, thus
leading to ad hoc cancellation of PPI. Nevertheless, those
patients might be at increased risk of recurrent complete AV
block during follow-up. Unfortunately, no study reports this
important fact in detail.
In the study by Urena et al. (9), in 8 of 79 patients with
new-onset LBBB (10.1%) a high degree of or complete AV
block developed during follow-up compared with 8 of 589
patients (1.4%) in the group without new-onset LBBB.
Table 1. The Most Important Studies Analyzing Outcome After TAVI With Respect to New-Onset LBBB
Houthuizen et al. (3) Testa et al. (4) Nazif et al. (6) Urena et al. (9)
n 679 818 1,151 668
Logistic EuroSCORE 16 23 25 21
Age, yrs 81 82 84 81
Balloon-expandable valve, % 43 0 100 100
Exclusion criteria Pre-existing LBBB and PPI;
post-procedural PPI
before discharge (15%)
Pre-existing LBBB and PPI;
post-procedural PPI
within 48 h (7%)
Pre-existing PPI and intraventricular
conduction disturbance;
paced rhythm on discharge ECG (3%)
Pre-existing LBBB and PPI;
post-procedural
PPI before discharge (7%)
Independent core laboratory
(ECGs/echocardiograms)
No No Yes No
LBBB group deﬁnition New onset New-onset persistent New-onset persistent New-onset persistent
New-onset (persistent) LBBB, % 34.3 27.4 10.5 11.8
Mortality with vs. without
new-onset LBBB
26.6% vs. 17.5% at 1 yr
(p ¼ 0.006)
18.7% vs. 19.7% at 1 yr
(p ¼ 0.1)
16.9% vs. 17.7% at 1 yr
(p ¼ 0.73)*
27.8% vs. 28.4% at 13 months
(p ¼ 0.40)
Rate of hospitalization for
heart failure
d No difference Higher if new-onset LBBB No difference
NYHA functional class d No difference No difference Higher if new-onset LBBB
Echocardiography data
available at follow-up
d 40%–45% 71% 83%
Improvement in LVEF d No difference at 1 yr Less improvement if
new-onset LBBBy
Less improvement if
new-onset LBBB
*Excluding patients with PPI before discharge. yMost pronounced in patients with baseline LVEF <35%.
ECG ¼ electrocardiogram; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart
Association; PPI ¼ permanent pacemaker implantation; TAVI ¼ transcatheter aortic valve implantation.
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138This points to a more than 7-fold increased risk of an
arrhythmia that may cause sudden cardiac death in patients
with new-onset LBBB after TAVI. Another study by
Urena et al. (7) reported a signiﬁcantly increased risk of
syncope in patients with LBBB after TAVI but without
PPI compared with patients without LBBB (20% vs. 0.7%;
p ¼ 0.001). Similarly, Nazif et al. (6) report signiﬁcantly
higher PPI rates after discharge in the new-onset LBBB
group (5.1% vs. 1.5%; p ¼ 0.01), one-half of which were
because of a high-degree of AV block.
In summary, although it is reassuring that several studies
have shown no important differences in mortality in cases of
new-onset LBBB after TAVI, we should continue to be
vigilant about ﬂuctuating AV conduction impairment after
TAVI or any symptoms suggesting transient complete AV
block. These patients should proactively undergo PPI. PPI is
a safe and rapid procedure that reliably prevents syncope
or bradyarrhythmic sudden cardiac death with minimal
adverse effects on long-term outcome (10).
It is now well established that complete LBBB or chronic
right ventricular pacing can adversely affect outcome (11).
However, these deleterious effects are most pronounced in
patients with pre-existing heart failure, and most TAVI
patients have preserved LVEF. Nazif et al. (6) also reported
a lack of LVEF improvement in patients with new-onset
LBBB after TAVI. This lack of improvement was mostly
seen in patients with a baseline LVEF <35%. Other studies
have found inconsistent effects of new-onset LBBB after
TAVI on LVEF (4,12). The reasons for this might be thedifferent rates of echocardiography available at follow-up
and the absence of independent echocardiography core
laboratories. Similarly, the effect of new-onset LBBB on
New York Heart Association functional class and the rate of
hospitalization for heart failure are inconsistent among
studies (4,6). We have to wait for larger studies that evaluate
the effect of new-onset LBBB after TAVI on LVEF and
heart failure parameters in a patient population with
impaired baseline LVEF. The impact of biventricular PPI in
this patient population will be interesting.
As indications for TAVI widen to younger patients with
fewer comorbidities, it can be expected that the relative
occurrence of conduction blockers will diminish.
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